IFF

IFF remains a scaled, formulation-driven ingredients supplier spanning Taste/Flavors, Scent, and Health & Biosciences, where customer stickiness, regulatory know-how, and application labs support pricing power and long product cycles. Recent footprint expansion in Latin America (new enzyme hub and application lab in Brazil) reinforces proximity-to-customer advantages in faster-growth emerging markets. Category mix looks favorable as Fine Fragrance strength and biosciences innovation can offset more cyclical pockets in food ingredients.

Financially, recent performance shows a restructuring-to-quality story: management cited 2025 comparable currency-neutral sales growth of about 2% and comparable adjusted operating EBITDA growth of about 7%, alongside net leverage of roughly 2.6x net debt to credit-adjusted EBITDA at year-end 2025. For 2026, IFF guided sales of $10.5–$10.8B and adjusted operating EBITDA of $2.05–$2.15B, implying modest growth despite portfolio pruning. GAAP profitability has been noisy (2025 GAAP loss per share has been reported), so valuation work should lean more on EBITDA and cash conversion than P/E.

Over the next 12 months, the thesis is that productivity, mix (premium scent, biosciences), and balance-sheet repair can drive steadier cash flow and multiple stabilization, but execution risk is real. Key catalysts are Q1 2026 results (scheduled for release May 5, 2026), progress monetizing/reshaping Food Ingredients, and follow-through on volume-led growth versus price. Key risks include raw material volatility, a demand slowdown in consumer categories, and any deterioration in leverage or credit metrics.

Recommendation: HOLD. The upside hinges on delivering the 2026 EBITDA plan and cleaner earnings quality, while the main offset is ongoing portfolio-transition and GAAP volatility that can keep sentiment fragile.